ERNEXA THERAPEUTICS INC (ERNA) Stock Price & Overview
NASDAQ:ERNA • US1140823089
Current stock price
The current stock price of ERNA is 0.1951 USD. Today ERNA is down by -5.34%. In the past month the price decreased by -36.86%. In the past year, price decreased by -93.2%.
ERNA Key Statistics
- Market Cap
- 5.687M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -3.25
- Dividend Yield
- N/A
ERNA Stock Performance
ERNA Stock Chart
ERNA Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to ERNA. When comparing the yearly performance of all stocks, ERNA is a bad performer in the overall market: 99.42% of all stocks are doing better.
ERNA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to ERNA. The financial health of ERNA is average, but there are quite some concerns on its profitability.
ERNA Earnings
ERNA Forecast & Estimates
ERNA Groups
Sector & Classification
ERNA Financial Highlights
Over the last trailing twelve months ERNA reported a non-GAAP Earnings per Share(EPS) of -3.25. The EPS increased by 97.07% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -241.67% | ||
| ROE | -587.21% | ||
| Debt/Equity | 0 |
ERNA Ownership
ERNA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.02 | 367.796B | ||
| AMGN | AMGEN INC | 15.37 | 189.224B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 172.517B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.4 | 110.97B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.97 | 79.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 47.19 | 42.718B | ||
| INSM | INSMED INC | N/A | 33.416B | ||
| NTRA | NATERA INC | N/A | 27.358B | ||
| BIIB | BIOGEN INC | 10.73 | 25.385B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.56 | 25.059B | ||
| MRNA | MODERNA INC | N/A | 20.21B | ||
| INCY | INCYTE CORP | 12.41 | 19.119B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.11B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ERNA
Company Profile
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Company Info
IPO: 1991-08-29
ERNEXA THERAPEUTICS INC
1035 Cambridge Street, Suite 18A
Cambridge MASSACHUSETTS US
Employees: 6
Phone: 16177986700
ERNEXA THERAPEUTICS INC / ERNA FAQ
Can you describe the business of ERNEXA THERAPEUTICS INC?
Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Can you provide the latest stock price for ERNEXA THERAPEUTICS INC?
The current stock price of ERNA is 0.1951 USD. The price decreased by -5.34% in the last trading session.
What is the dividend status of ERNEXA THERAPEUTICS INC?
ERNA does not pay a dividend.
How is the ChartMill rating for ERNEXA THERAPEUTICS INC?
ERNA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
What is ERNEXA THERAPEUTICS INC worth?
ERNEXA THERAPEUTICS INC (ERNA) has a market capitalization of 5.69M USD. This makes ERNA a Nano Cap stock.
What is the outstanding short interest for ERNEXA THERAPEUTICS INC?
The outstanding short interest for ERNEXA THERAPEUTICS INC (ERNA) is 0.47% of its float.